Merck: Smart Value For Potentially Strong Total Returns

JuSun It’s almost the end of the year, and is a good time to re-evaluate one’s portfolio in terms of potential winners and losers next year. With the market chasing growth stocks to nosebleed valuations, I believe better opportunities can be found to similar moat-worthy enterprises that are trading at far more reasonable valuations with a dividend kicker. This brings me to Merck (NYSE:MRK), which I last covered here in October of last year, noting the expansion of its highly profitable Keytruda drug and ...